It's a waste of time and energy to respond to some
Post# of 72440
Mr. Ehrlich has stated that he would like to see IPIX become a research and royalty company. I see no reason to question his word. I agree with Grotty that if a great deal came along, he would certainly have a responsibility to consider it and present it to shareholders.
However, I think most of our definitions of "great deal" involve high valuations for our first-in-class drugs, especially our first new class of antibiotics since 1987.